1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Bio-Techne Corporation

Bio-Techne Corporation

TECH
Bio-Techne CorporationUS flagNASDAQ Global Select
56.03
USD
-0.14
- -
8.77BMarket Cap

Total Valuation

Bio-Techne Corporation carries a market capitalization of 8.77B, placing it among publicly traded companies globally. Its enterprise value stands at 8.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.77B
Enterprise Value8.21B

Share Statistics

Bio-Techne Corporation currently has 156.52M shares outstanding.

Shares Outstanding156.52M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Bio-Techne Corporation trades at a trailing price-to-earnings ratio of 74.24. The price-to-sales ratio is 6.72, and the price-to-book ratio stands at 7.09.

PE Ratio74.24
PS Ratio6.72
PB Ratio7.09
P/TBV Ratio10.32
P/FCF Ratio25.57
P/OCF Ratio27.58

Enterprise Valuation

On an enterprise value basis, Bio-Techne Corporation trades at an EV/EBITDA multiple of 20.81 and an EV/FCF ratio of 25.09. The EV/Sales ratio of 6.78 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 27.91 provides insight into valuation relative to core operating earnings.

EV / Sales6.78
EV / EBITDA20.81
EV / EBIT27.91
EV / FCF25.09

Financial Position

Bio-Techne Corporation maintains a current ratio of 4.49, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.92, indicating elevated leverage, while an interest coverage ratio of 40.75 demonstrates strong ability to service its debt obligations.

Current Ratio4.49
Quick Ratio2.77
Debt / Equity13.92
Debt / EBITDA0.74
Interest Coverage40.75

Financial Efficiency

Bio-Techne Corporation posts a return on equity of 9.35 and a return on invested capital of 9.11.

Return on Equity (ROE)9.35
Return on Assets (ROA)4.22
Return on Invested Capital (ROIC)9.11
Return on Capital Employed (ROCE)7.64
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.16

Taxes

Over the trailing twelve months, Bio-Techne Corporation has paid 37.58M in income taxes, reflecting an effective tax rate of 25.54.

Income Tax37.58M
Effective Tax Rate25.54

Stock Price Statistics

Bio-Techne Corporation's stock has gained approximately 13.19192% over the past 52 weeks. The 50-day moving average sits at 52.41, while the 200-day moving average is 57.46.

Beta (5Y)N/A
52-Week Price Change13.19192%
50-Day Moving Average52.41
200-Day Moving Average57.46
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Bio-Techne Corporation generated 1.21B in revenue and converted that into 109.56M in net income, yielding earnings per share of 0.70. EBITDA reached 394.63M, while operating income came in at 294.30M.

Revenue1.21B
Gross Profit786.49M
Operating Income294.30M
Pretax Income147.14M
Net Income109.56M
EBITDA394.63M
EBIT294.30M
Earnings Per Share (EPS)0.70

Balance Sheet

Bio-Techne Corporation holds 209.82M in cash and equivalents against 290.32M in total debt, resulting in a net debt position of -9.82M. Total book value stands at 1.15B, with working capital of 534.77M providing operational flexibility.

Cash & Cash Equivalents209.82M
Total Debt290.32M
Net Debt-9.82M
Equity (Book Value)1.15B
Book Value Per Share7.37
Working Capital534.77M

Cash Flow

Bio-Techne Corporation produced 294.86M in operating cash flow over the past twelve months. After subtracting -25.26M in capital expenditures, free cash flow totaled 269.60M - equivalent to 1.73 per share.

Operating Cash Flow294.86M
Capital Expenditures-25.26M
Free Cash Flow269.60M
FCF Per Share1.73

Margins

Bio-Techne Corporation operates with a gross margin of 64.96, reflecting its pricing power and cost economics. The operating margin of 24.31 and net profit margin of 9.05 provide insight into operational efficiency.

Gross Margin64.96
Operating Margin24.31
Pretax Margin12.15
Profit Margin9.05
EBITDA Margin32.59

Dividends & Yields

The company's payout ratio of 45.47 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.32
Dividend YieldN/A
Payout Ratio45.47
Shareholder Yield2.78
FCF Yield3.91

Stock Splits

Bio-Techne Corporation's most recent stock split took place on November 30, 2022 with a 1:4 split ratio.

Last Split Date11/30/2022
Split Ratio1:4

Scores

Bio-Techne Corporation posts an Altman Z-Score of 14.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score14.02